Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343339
Award Amount
$5,000,000.00
Maximum Amount
$5,000,000.00
Assistance Type
Other
Funding Source
Federal
Implementing Entity
National Institutes of Health
Due Date
Where the Opportunity is Offered
All of California
Eligible Applicant
State Government
County/Local Government
Special District
School
Tribal Government
NGO
Nonprofit
Business
Other
Additional Eligibility Information
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Contact
NIH Grants Information
Description

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.

Category
Community Outreach and Capacity Building

Similar Oppportunities

Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional)
Last Updated